Car-NK cell therapy for heart amyloidosis
Part of Heart & circulation clinical trials.
This study tests a new treatment called CAR-NK cells for people with amyloidosis that has affected the heart. The treatment uses specially modified immune cells to target and attack the abnormal protein deposits causing the disease. It may be an option for people who haven't responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of amyloidosis with heart involvement.
- You must have tried at least one standard treatment (like bortezomib or a CD38 antibody) and it didn't work well enough.
- Your heart function must be within certain limits (e.g., not too severe heart failure).
- You must have adequate blood cell counts, liver, and kidney function.
- You must not have certain other health conditions, like uncontrolled infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—selinexor, daratumumab, and dexamethasone—for people with a rare condition where abnormal proteins build up in the heart. The goal is to see if this combination can help reduce these proteins and improve heart function.
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Hear when a new Light Chain Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.